Banca de QUALIFICAÇÃO: ANTONIO CARLOS QUEIROZ DE AQUINO

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
STUDENT : ANTONIO CARLOS QUEIROZ DE AQUINO
DATE: 30/08/2024
TIME: 09:00
LOCAL: REMOTA - https://meet.google.com/msc-jdmj-ttv
TITLE:

Treatment of antidepressant-induced sexual dysfunction in women: A Systematic Review of Clinical Trials

KEY WORDS:

Women; Sexual Dysfunction; Therapeutics; Antidepressive Agents

PAGES: 28
BIG AREA: Ciências da Saúde
AREA: Medicina
SUMMARY:

Purpose: Sexual dysfunction caused by antidepressant use is a significant public health concern, often leading to reduced adherence to antidepressant treatment and worsened mental health. Pharmacological therapies might offer potential solutions for this issue. This study aims to evaluate the effectiveness of pharmacological treatments in managing antidepressant-induced sexual dysfunction in women.

Methods: We searched PubMed, Cochrane, Scopus, Web of Science, Embase, PsycINFO, and ClinicalTrials.gov databases up to July 3, 2024. We included randomized controlled trials comparing pharmacological treatments with placebo. The Cochrane Risk of Bias tool (RoB 2.0) was used to assess bias risk. Data synthesis was conducted using RevMan5.4, and the strength of the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.

Results: Thirteen studies with a total of 1,064 women experiencing antidepressant-induced sexual dysfunction met the criteria for this systematic review. Participants’ mean age ranged from 28 to 48 years. Interventions included amantadine, Aphrodite, bupropion SR, buspirone, ephedrine, maca root, mirtazapine, olanzapine, Rosa damascena, saffron, sildenafil, testosterone, the compound VML-670, and yohimbine. Risk assessments showed two studies as low risk, eight with concerns, and three as high risk. The GRADE rating for the certainty of evidence was moderate.

Conclusion: A variety of medications and complementary/alternative medicine approaches are available for treating antidepressant-induced sexual dysfunction. Our systematic review provides a comprehensive overview of the current scientific evidence. Bupropion appears to be the most effective pharmacological option for this condition in women. However, the evidence quality is moderate, and further clinical trials focused on women with rigorous methodologies are needed to strengthen these findings

COMMITTEE MEMBERS:
Presidente - 1199080 - ANA KATHERINE DA SILVEIRA GONCALVES DE OLIVEIRA
Externo à Instituição - JOSE MANUEL PEREZ MARMOL
Externa à Instituição - LUCIA ALVES DA SILVA LARA